Skip to content

High-Voltage Pulsed Radiofrequency of the Lumbar Dorsal Root Ganglion for the Treatment of Chronic Lumbar Radicular and Neuropathic Pain; A Prospective, Doble-blinded and Randomized Controlled Trial

High-Voltage Pulsed Radiofrequency of the Lumbar Dorsal Root Ganglion for the Treatment of Chronic Lumbar Radicular and Neuropathic Pain; A Prospective, Doble-blinded and Randomized Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06264297
Acronym
Radiofrequency
Enrollment
98
Registered
2024-02-16
Start date
2023-02-20
Completion date
2027-12-31
Last updated
2024-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Radiculopathy, Pulsed Radiofrequency

Brief summary

The management of chronic lumbar radicular and neuropathic pain is complex and the treatment success rates are low. Pulsed radiofrequency (PRF) has been described in these cases. In order to determine whether high-voltage PRF show better results than PRF a prospective, doble-blinded and randomized study is conducted in patients with chronic lumbar radicular and neuropathic pain.

Interventions

PROCEDURERadiofrequency

Pulsed radiofrequency (PRF) is a nonablative pain treatment that uses radiofrequency current in short high-voltage bursts, resulting in interruption of nociceptive afferent pathways. This study aims to show how the variation in radiofrequency voltage applied to the dorsal root ganglion (DRG) affects the treatment of neuropathic pain.

Sponsors

Consorci Sanitari de Terrassa
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients over 18 years of age. * Unilateral pain radiating to the lower extremity (with or without lumbar pain), which clinically corresponds to the path of the corresponding dermatomes. * Correlation between clinical symptoms and lesion observed by magnetic resonance imaging (MRI). * Radicular syndrome of three months or more of evolution. * Normal or pathological electromyogram (EMG). * Pain with neuropathic characteristics confirmed by the DN4 neuropathic pain questionnaire. * Patients with a previous positive block diagnosis. * Patients who have signed the informed consent document.

Exclusion criteria

* Patients under 18 years of age. * Patients with non-radicular low back pain. * MRI not consistent with the patient's symptoms. * Patients with peripheral neuropathy of the lower extremities. * Patients with a history or current diagnosis of serious mental disorder. * Patients with moderate or severe cognitive impairment, or evidence of acute or subacute confusional syndrome. * Infection at the puncture site. * Coagulation disorders. * Pregnant patients. * Patients who refuse to sign the informed consent document. * Patients allergic to radiological contrast.

Design outcomes

Primary

MeasureTime frameDescription
OSWESTRY LOW BACK DISABILITY QUESTIONNAIREFrom enrollment to the end of treatment at 6 monthsthis questionnaire has been designed to give us information as to how your back pain has affected your ability to manage everyday life

Secondary

MeasureTime frameDescription
DN4 - QUESTIONNAIREFrom enrollment to the end of treatment at 6 monthsDN4 - QUESTIONNAIRE To estimate the probability of neuropathic pain, please answer yes or no for each item of the following four questions.
Visual Numeric ScaleFrom enrollment to the end of treatment at 6 monthsranging from 0 to 10 was used to measure pain intensity
Categorical scaleFrom enrollment to the end of treatment at 6 monthsuses adjectives, such as mild, moderate, severe, and excruciating, to describe pain levels.
patient global impression of improvement (pgi-i) scoreFrom enrollment to the end of treatment at 6 monthsis a transition scale that is a single question asking the patient to rate their urinary tract condition now, as compared with how it was prior to before beginning treatment

Countries

Spain

Contacts

Primary ContactMaria Martinez
mariamartinezgarcia@gmail.com+34650528215
Backup ContactMaria Martinez
mariamartinezgarcia@gmail.com650528215

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026